Review

Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function

Filippo Molica 1,2,*, Florian B. Stierlin 1,2,3, Pierre Fontana 3,4 and Brenda R. Kwak 1,2

1 Department of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland; florian.stierlin@gmail.com (F.B.S.); brenda.kwakchanson@unige.ch (B.R.K.)
2 Department of Medical Specializations, Cardiology, University of Geneva, 1211 Geneva, Switzerland
3 Geneva Platelet Group, University of Geneva, 1211 Geneva, Switzerland; pierre.fontana@hcuge.ch
4 Division of Angiology and Haemostasis, Geneva University Hospitals, 1211 Geneva, Switzerland
* Correspondence: filippo.molica@unige.ch; Tel.: +41-22-379-57-52

Abstract: The three major blood cell types, i.e., platelets, erythrocytes and leukocytes, are all produced in the bone marrow. While red blood cells are the most numerous and white cells are the largest, platelets are small fragments and account for a minor part of blood volume. However, platelets display a crucial function by preventing bleeding. Upon vessel wall injury, platelets adhere to exposed extracellular matrix, become activated, and form a platelet plug preventing hemorrhagic events. However, when platelet activation is exacerbated, as in rupture of an atherosclerotic plaque, the same mechanism may lead to acute thrombosis causing major ischemic events such as myocardial infarction or stroke. In the past few years, major progress has been made in understanding of platelet function modulation. In this respect, membrane channels formed by connexins and/or pannexins are of particular interest. While it is still not completely understood whether connexins function as hemichannels or gap junction channels to inhibit platelet aggregation, there is clear-cut evidence for a specific implication of pannexin1 channels in collagen-induced aggregation. The focus of this review is to summarize current knowledge of the role of connexins and pannexins in platelet aggregation and to discuss possible pharmacological approaches along with their limitations and future perspectives for new potential therapies.

Keywords: platelet aggregation; collagen; connexins; pannexins

1. Introduction

Atherosclerosis is an inflammatory disease affecting medium-to-large sized arteries and leading to the formation of atheroma. Plaque formation starts during the early years [1] favored by risk factors inducing endothelial dysfunction as an initiating stage of the disease. Atherosclerosis evolves through different stages, sometimes leading to the formation of unstable atherosclerotic plaques prone to rupture and to acute ischemic events [2] via the formation of a platelet-rich thrombus. Strong links between platelet aggregation and atherogenesis have been shown and will be discussed here.

The initial vascular lesion increases endothelium permeability, adhesiveness for leukocytes and platelets, and it induces procoagulant properties [3]. Inflammation stimulates smooth muscle cell accumulation at the vascular lesion and release of mediators (cytokines, growth factors) from monocyte-derived macrophages and T lymphocytes. This further enhances the development of atherosclerotic plaques through a vicious circle (recruitment of more T lymphocytes, monocytes and smooth muscle cells) [4,5]. In parallel, lipids accumulate in the lesion, are taken up by macrophages, lipid-laden macrophages die and a lipid core is formed. A fibrous cap, composed principally of smooth
muscle cells that originate from the media, also develops with variable levels of stability depending on the quantity of extracellular matrix components (mainly collagen) produced by these cells [6].

Rupture of the fibrous cap and erosion of the intimal surface of the atheroma are two mechanisms leading to exposure of the plaque’s thrombogenic material to the blood [2]. These mechanisms are mediated by different protagonists such as cytokines, matrix metalloproteinases, or endothelial Toll-like receptors [7,8]. Thrombus formation is a rapid process in which platelets play a major role by going through different steps: platelet adhesion, activation and aggregation. Various ion channels such as P2X1 purinergic receptors, Orai1 store-operated channels, connexin and pannexin channels as well as α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-aspartate (NMDA) glutamate receptors receive increased attention as potential regulators of platelet function and thrombus formation [9,10]. In this review, we describe the major steps leading to thrombus formation, which will be explained separately for didactic reasons, with a particular focus on the role of connexins and pannexins in platelet aggregation.

2. Platelet Function: From Plaque Rupture to Thrombus Formation

2.1. Platelet Adhesion and Activation

With rupture of the fibrous cap, the highly thrombogenic sub-endothelial matrix is exposed to circulating platelets [2]. This contact initiates primary hemostasis, with the first step being platelet adhesion to the site of vascular injury.

Two pathways are known to participate in platelet adhesion, namely, the direct and the indirect pathways [11]. In conditions of rapid blood flow (such as arterial flow), a strong and rapid connection between the vascular wall and platelets needs to be established. This is the role of the indirect pathway, which works principally through one glycoprotein (GP) called von Willebrand factor (vWF). The adjective “indirect” refers to the necessity of vWF to establish binding between collagen and platelets. vWF is found in the sub-endothelial matrix, in circulating blood as an inactive form, in the Weibel Palade bodies of endothelial cells and in α-granules of platelets [12]. When collagen is exposed, vWF binds to it and undergoes conformational changes [13]. These changes occur at high shear stress and uncover the binding site for the GPIb-IX-V complex on vWF [11]. The binding of vWF to GPIb-IX-V allows the tethering of platelets onto the vascular wall at the site of vascular injury allowing platelet adhesion to collagen (Figure 1). Of note, in order to bind to collagen, vWF must first be in an immobilized form, which implicates a process not yet fully understood [14].

The direct pathway corresponds to the interaction between sub-endothelial structures such as collagen with specific receptors on the surface of platelets. Collagen receptors are named α2β1 and GPVI [11]. The direct pathway plays its role in conditions of low blood flow and reinforces platelet–platelet adhesion. Through this mechanism, a monolayer of activated platelets is created, which permits the further recruitment and the growth of the platelet plug [15].

Once the adhesion complex is stable, platelet activation takes place involving a shape change as well as an initial secretion of granules. The transformation of the integrin αIIbβ3 receptor from its resting low-affinity state to a high affinity state ends the activation process, subsequently mediating platelet aggregation [16]. Human platelets can be activated by numerous agonists like thrombin, which is produced in small quantities after the binding of tissue factor to coagulation factors at the surface of activated platelets [17]. This allows for further activation and recruitment of resting platelets through the cleavage of protease-activated receptor (PAR)-1 and PAR-4 [18], as well as for the subsequent platelet shape change and intra-cytoplasmic calcium release [15,19]. However, despite the important role of thrombin, collagen remains the central actor in the context of atherothrombosis.
2.1.1. Collagen

Because of its major role in platelet activation and adhesion, platelet–collagen interaction is a major focus of research. Platelets can bind collagen through several receptors such as collagen GPVI and the integrin receptors α2β1 and αIIBβ3 (Figure 2). While GPVI participates in platelet activation, α2β1 has a more important role in platelet adhesion and αIIBβ3 in aggregation. Therefore, GPVI and α2β1 will be discussed in the following section.

Glycoprotein VI

The GPVI receptor is a 319 amino-acid GP expressed on platelets and megakaryocytes [20] but also on other cells [21]. GPVI responds exclusively to collagen as proven in patients with auto-immune thrombocytopenia leading to a deficiency in this receptor [22]. Structurally, GPVI is a complex composed of an extracellular part with two immunoglobin-like domains (GPVI molecules) non-covalently bound to an intracellular part, the Fc receptor (FcR) γ-chain [23,24]. When bound to fibrinogen, cross-linking and subsequent activation of GPVI/FcR γ-chain complex occurs and leads to Src kinase-dependent (Fyn and Lyn) phosphorylation of an Immunoreceptor Tyrosine-based Activation Motif (ITAM) present in the FcR γ-chain portion [25]. This favors the recruitment and the auto-phosphorylation of Spleen tyrosine kinases (Syk) and the subsequent phosphorylation of several intracellular effectors such as phospholipase Cγ2 (PLCγ2) or phosphoinositide-3 kinase (PI3-kinase) [26].

PLCγ2 catalyzes the formation of the second two messengers, namely, 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) [27], from phosphatidylinositol 4,5-bisphosphate [28,29]. IP3 induces a rapid raise of cytoplasmic calcium concentration through mobilization of intracellular stores (from the

Figure 1. Platelet adhesion. (1) Indirect adhesion pathway: once circulating platelets are exposed to the thrombogenic subendothelial matrix, von Willebrand factor (vWF) binds to collagen and undergoes a conformational change permitting its subsequent binding to the GPIb-IX-V (GP, glycoprotein) complex. This mechanism allows for the tethering of platelets to the vascular wall and subsequent stronger adhesion through the direct pathway; (2) Direct adhesion pathway: once platelets are slowed down, binding of collagen to GPVI and α2β1 occurs and promotes stable platelet adhesion to the vascular wall. Other receptors (ADP, ATP and thromboxane A2) are shown here but do not play a role in platelet adhesion.
platelet dense tubular system) and influx from extracellular space leading to platelet activation [30]. DAG activates protein kinase C (PKC) [31], which leads to thromboxane A2 (TXA2) release [32].

**Figure 2.** Platelet activation: Once platelets arrest on the vascular wall, activation occurs under the control of several molecules, among which collagen and thrombin. (1) Collagen-induced platelet activation: binding of sub-endothelial collagen fibrils to platelet receptor GPVI induces cross-linking and subsequent activation of GPVI/FcR-γ-chain complex (an intracellular part of GPVI). This activation leads, through a cytoplasmic phosphorylation cascade, to an increase in cytoplasmic calcium concentration and a subsequent platelet shape change, granule secretion and/or increase in affinity of platelet surface receptors. The increase in affinity of α2β1 enhances its binding to collagen. The final step in platelet activation is the transformation of αIIbβ3 from its low to its high-affinity state in order to promote platelet aggregation; (2) Thrombin mediated platelet activation: tissue factor in its active form binds to and activates FVII, which promotes an initial generation of small quantities of thrombin and a later burst in thrombin generation (through a cascade comprising other coagulation factors). Thrombin then favors platelet activation by cleavage of protease-activated receptors (PARs) also leading to increased calcium concentration and decreased cyclic adenosine monophosphate (cAMP).

GPVI activates the PI3-kinase, resulting in phosphatidylinositol 3,4,5-trisphosphate (PIP3) production [26], which is thought to play a role in PLCγ2 regulation [33]. The specific affinity of GPVI for collagen, and its compulsory action during collagen-induced platelet aggregation, makes GPVI a major signaling receptor for collagen in platelets.

Integrin α2β1

α2β1 (also known as GPIa-IIa) is an integrin expressed on several cell types including lymphocytes [34] and fibroblasts [35], and is required for platelet adhesion to the vascular wall [36]. It works as an extracellular receptor for collagen and/or laminins depending on the cell type expressing it [37]. Similar to all other integrins, α2β1 displays a heterodimeric structure composed of an α- (α2) and a β-subunit (β1) with a transmembrane domain and intracellular domains [38].

α2β1 exists in a low-affinity state with its extracellular domain into a close conformation. It is activated by GPVI to form a high-affinity state (with conformational changes in extracellular domains) thus permitting stronger binding to collagen [11]. α2β1 activation is induced by an “inside-out” process, where proteins bind to the intracellular α- and β-tails of the receptor and provoke a conformational change in the extracellular domain leading to the high-affinity state [39,40]. As previously mentioned,
numerous proteins can interact with the cytoplasmic tails of integrins and talins, which are strong activators for α2β1 [39]. Talin, a cytosolic protein abundantly found in platelets [41], is composed of a head domain (talin-H) and a rod domain (talin-R). The head domain can bind to the integrin β cytoplasmic domain [42] and induce a disruption in salt bridges from the cytoplasmic tails, thus exposing α2β1 extracellular binding site, such as the α2-I domain [40] and enhancing α2β1 affinity for collagen [42]. Of note, other agonists such as ADP, thrombin or collagen-related peptide (CRP) have been shown to activate α2β1 from its low to its high-affinity state [43]. Given the various kinetics of α2β1, Jung and Moroi [43] proposed a multistate model of α2β1 activation where three affinity states exist. However, whether the process occurs sequentially or not is yet unknown.

α2β1 is also thought to generate intracellular signals via an “outside-in” process [44]. This integrin is known for having a supplementary inserted domain (l-domain) on the α2 globular head containing a high-affinity binding site for collagen (GFEOGR motif) [45] and a metal ion-dependent adhesion site (MIDAS) [46]. MIDAS permits a magnesium-dependent binding to collagen [34], which induces conformational changes in the aforementioned I-domain [38]. It is unclear whether collagen binding to α2β1 results in the activation of intracellular signaling pathways, but several observations support such a hypothesis. Jarrahgein, a specific inhibitor of α2β1 acting by cleavage of the GPla subunit [47], has been shown to inhibit α2β1 activation and tyrosine activation in response to collagen [48]. However, this effect may be surmounted by increasing collagen concentrations [49]. Moreover, a selective peptide for α2β1 [50] has been developed, which did not succeed in stimulating tyrosine phosphorylation [51], an expected intracellular effect. It is likely that GPVI and α2β1 operate synergistically in both platelet adhesion and activation and that GPVI is not able to control all aspects of collagen-induced platelet activation and aggregation. This observation is supported, among others, by the fact that collagen-binding to α2β1 is already possible in the low-affinity (non-activated) state [52].

2.2. Platelet Aggregation, Thrombus Growth and Stabilization

The final step of platelet activation is to promote integrin αIIbβ3 (previously known as GPIIb-IIIa) change from its low- to its high-affinity state, which allows irreversible αIIbβ3 binding to fibrinogen and vWF and consequently leads to stable platelet aggregates [53–55] (Figure 3). αIIbβ3, the most abundant integrin on platelet surface [56], is a heterodimer composed of an extracellular part containing two subunits (αIIb and β3) linked by non-covalent bonds, a single transmembrane domain and a small cytoplasmic domain [54,57,58]. Similar to α2β1, this conformational change is mediated through an “inside-out” mechanism, but αIIbβ3 is also able to function via an “outside-in” process [59]. As αIIbβ3 is a central player in platelet aggregation, numerous proteins influence its conformational change and more than 20 have already been described [60]. Of these proteins, talin is thought to be of particular importance for αIIbβ3 activation [42]. Some other proteins named Kindlins (and particularly Kindlin-3) have also been described as regulators of talin–integrin interaction and act as stimulators for αIIbβ3 activation [61]. Given the numerous molecules involved, the complete pathway to αIIbβ3 activation and modulation is still not clearly understood. The actual consensus is that intracellular calcium and DAG levels stimulate the production of Rap1, a small GTPase acting as a potent regulator of integrin activation [62]. Rap1 needs an effector molecule called the Rap1-GTP-interacting adaptor molecule (RIAM) to modulate the interaction between talin and Rap1-GTP [63] and activate the “inside-out” signaling. Of note, as Rap1 depletion does not lead to complete abolishment of platelet aggregation, other activation pathways independent of this protein may be involved [64].

Similar to other integrins, “outside-in” signaling also exists with αIIbβ3. After αIIbβ3 activation, conformational changes in its transmembrane and cytoplasmic domains occur [65]. Microclustering also occurs, which is an imprecisely defined process where receptors cluster at the cell surface [66]. These modifications induce several intracellular events leading to stable platelet adhesion, granule secretion, clot retraction and also cell motility or gene expression [67,68]. A well-known event in this signaling cascade is the binding of a G-protein subunit (Ga13) to the αIIbβ3 cytoplasmic domain of β3, which stimulates the activation of Src family kinases (SFKs) [69]. SFKs are implicated in
cell migration and spreading [70] and participate in the outside-in signaling through three different mechanisms. The first mechanism involves the phosphorylation of two tyrosine-site motives in the β3 cytoplasmic tail [71], which negatively regulates talin binding [72] (thus playing a role in clot dissemination), and protection from calpain cleavage (which normally inhibits cell spreading) [73]. A second mechanism involves the stimulation of a GTPase activating protein [74] by a c-Src tyrosine kinase in the β3 cytoplasmic tail of αIIbβ3, which permits inhibition of RhoA [75], a GTPase regulating cell contractility and the formation of protrusive structures for cell spreading [76]. Finally, SFKs can also activate Syk [77], which phosphorylates FcγRII, thus leading to PLCγ2 activation (and therefore platelet activation) through the assembly of an intracellular complex [78].

**AGGREGATION & STABILIZATION**

Figure 3. Platelet aggregation and clot stabilization. Platelet aggregation: αIIbβ3 high-affinity state permits its binding to fibrinogen thus initiating the “outside-in” signaling process and promoting stable aggregation. Extension and stabilization of the platelet clot: Through paracrine secretion of platelet agonists (notably adenosine diphosphate (ADP), thromboxane A2 (TxA2) and thrombin), extension of the platelet plug occurs. These agonists act on different receptors with various signaling mechanisms but with the same final effect, i.e., increased intracellular calcium and decreased cAMP concentrations. This promotes platelet activation, aggregation, recruitment of more platelets and shape change. Inter-platelet close contact allows stronger platelet binding and thus stabilisation of the clot. Several molecules and receptors are known to participate in this process such as CD40-ligand (CD40L), ephrin B1 ligand and ephrine kinases receptor, or αIIbβ3.

After platelet activation and once αIIbβ3 is in its high affinity state, platelet aggregation as well as thrombus extension and stabilization occur. Extension is possible via paracrine action of platelet soluble agonists, mainly thrombin (as described above) but also ADP and TxA2, which induce cAMP decrease and cytoplasmic calcium increase via the activation of their respective receptors P2Y1/P2Y12 (for ADP) and TPα/TPβ (for TxA2) [15,79–84].

The freshly formed platelet plug needs stabilization and strong platelet contacts to avoid its dissolution. Different signaling mechanisms strengthen thrombus stability. Of these mechanisms, the “outside-in” process linked to αIIbβ3 [67] or the binding between αIIbβ3 and CD40L, a member of the tumor necrosis factor family of ligands that is expressed on activated platelets, play a major role [85]. Other inter-platelet mechanisms promoting clot stabilization include the binding of Eph receptor kinase to its ephrin B1 ligand (which also participate in “outside-in” process) [86] (Figure 3).
2.3. Towards New Antiplatelet Agents

The currently used antiplatelet agents target several key actors of platelet function such as TxA₂ generation (aspirin) or the P₂Y₁₂ receptor (anti-P₂Y₁₂ drugs). The main adverse event related to these drugs is bleeding and huge efforts are being done to identify new drug targets, allowing a fine-tuning of platelet function with a more favorable benefit/risk ratio.

Among potential targets [87], GPVI as well as some types of membrane channels are of particular interest [88]. Indeed, various calcium channels such as the ATP-gated P₂X₁ purinergic receptors, the Orai1 store-operated channels, Kv1.3 voltage-gated channels as well as AMPA and NMDA glutamate receptors have been shown to participate in the regulation of platelet function [10]. In the following sections of this review, we will exclusively focus on the role of two other types of membrane channels, pannexins (Panx) and connexins (Cxs), of which the essential role in platelet function is increasingly recognized.

3. Connexins and Pannexins

Cxs are members of a family of proteins encoded by 20 to 21 different mammalian genes, which are expressed in a large variety of tissues [89,90]. Cx genes are classified according to sequence homology and are divided into five subfamilies [91]; cardiovascular Cxs belong mostly to the α subfamily (GJA). Cx proteins are named after their specific molecular weight in kDa (for instance, Cx43). The general structure of a Cx consists of four α-helical transmembrane domains (TM1-TM4) and two extracellular loops (EL1 and EL2) that are highly conserved among the family members. The amino-terminal (NT), carboxy-terminal (CT) parts and the intracellular loop (IL), which are all located in the cytoplasm, differ considerably in both length and composition and are nearly unique to each Cx type. Cxs are synthesized in the endoplasmic reticulum (ER) and oligomerize in the ER/Golgi or trans-Golgi network to form hexameric connexons [92,93]. After that, connexons are transported to the plasma membrane along microtubules. When two cells are closely apposed, connexons from one cell can dock with their counterparts in the neighboring cell and form a gap junction channel enabling the intercellular exchange of ions and small messenger molecules up to ~1 kDa. These channels are called homomeric, heteromeric or heterotypic depending on whether they are composed of identical or different Cx isoforms [94] (Figure 4A). Under specific conditions, connexons may function as a hemichannel allowing the permeation of ions and small metabolites such as calcium, ATP, ADP and glutamate [95,96]. A variety of factors regulate Cx channel gating, including voltage, pH, and Ca²⁺, phosphorylation, S-nitrosylation and other post-translational modifications [97–99]. Recently, increasing evidence points to an important function for the so-called connexin interactome, a network with the Cx being the central mediator [100,101]. Maintenance of hemichannel and/or gap junction functionality and integrity is fundamental to conserve intercellular communication and homeostasis in a wide range of tissues. The essential nature of Cxs in tissue homeostasis is further emphasized by the multitude of pathologies that are linked to mutations and polymorphisms in Cx genes [90,102]. The expression and function of Cxs in platelets has only recently attracted research interest.

Panx represent yet another small family of three transmembrane proteins (Panx1–3) that were discovered only in the year 2000 [103]. The Panx1 and Panx3 genes are both located on human chromosome 11, while the Panx2 is located on chromosome 22 [104]. The Panx proteins exhibit a topology analogous to Cxs (Figure 4B), although they share no sequence homology [105–107]. Initial characterization of Panx1 oligomerization showed that this Panx forms hexameric single-membrane channels (Figure 4C) [108]. Panx1 is ubiquitously present in human and mouse tissues, whereas Panx2 seems to be predominant in the brain and the central nervous system, and Panx3 is mostly expressed in bones, cartilage and skin [109–111]. The general expression pattern of Panx1 likely explains that the vast majority of basic and clinical studies focus on this Panx. Important glycosylation sites are found in the ELs of Panx1 and Panx3 [107,108]. The occupation of these sites likely prevents docking of pannexons (Figure 4C). It is now generally accepted that Panx function as single-membrane channels.
Similar to Cx hemichannels, Panx channels allow for intercellular communication by the release of small molecules such as purines that can signal via targeting surface receptors in a paracrine, or even in an endocrine, fashion. However, it is important to keep in mind that Panx channels can be opened at physiological membrane potential and extracellular calcium by several mechanisms: mechanical stretch, phosphorylation by Src kinases, caspase cleavage of its C-terminus and following purinergic P2 receptor stimulation [107,110,112–114]. Connexon opening is generally induced under more pathological conditions such as low extracellular calcium or very large depolarizations [115]. As described above, purinergic receptors are expressed in platelets where they are major players in platelet activation. In fact, ADP-dependent activation of metabotropic P2Y1 and P2Y12 purinergic receptors occurs after platelet stimulation through thrombin, TxA2 or collagen. On the other hand, the ionotropic receptor P2X1, in response to ATP stimulation, contributes to the increase in intracellular calcium leading to the initial shape change of platelets followed by aggregation [116]. While the role of Cxs and Panx1 channels in the regulation of vascular tone, the immune response and in neurophysiology is increasingly recognized [99,117–119], their role in platelet function has only recently been discovered. The next paragraphs summarize these new advances.

Figure 4. Connexin gap junctions and Pannexin1 channels. (A) Homotypic or heterotypic gap junction channels assemble in the extracellular space by the docking of two homomeric or heteromeric connexons from neighboring cells. Connexons are formed by the hexamerization of six Cx subunits (e.g., Cx37 in red and Cx43 in blue) and may function as hemichannels under particular conditions; (B) Similar to connexins, pannexins, including Panx1, are membrane proteins composed of four transmembrane helices (TM1-TM4), two extracellular loops (EL1 and EL2), one intracellular loop (IL) and an N- and a C-terminal end located in the cytoplasm (NT and CT); (C) Six Panx1 subunits assemble into a pannexon. However, due to glycosylation on the N254 residue located in EL2, Panx1 is unable to form gap junctions and functions exclusively as a single-membrane channel.
3.1. Pannexin1 and Platelet Aggregation

Upon vascular damage, exposure of sub-endothelial collagen and vWF to the blood flow induces the recruitment of platelets in order to promote primary hemostasis at the site of the injury [120]. Adhering platelets then undergo shape change, release messengers including ADP and ATP, and synthetize molecules reinforcing their activation and promoting further platelet recruitment and aggregation [120,121]. Given the crucial role of ADP and ATP release in the activation of purinergic signaling during platelet activation [87], the recent finding that Panx1 is expressed at the surface of human platelets [122,123] paved the way for studies investigating the role of Panx1 channels in platelet aggregation and thrombosis. It was first demonstrated that exposure of platelets to the non-specific Panx1 inhibitors probenecid (Pbn) and carbenoxolone (Cbx) dampened the influx of calcium, subsequent ATP release and aggregation in response to low concentrations of thrombin, collagen or the TxA2 analogue U46619 [122]. It was hypothesized that Panx1 plays a role in a granule-independent ATP release amplifying the aggregation response and calcium influx through P2X1 receptor [122]. This hypothesis was further strengthened by another independent study demonstrating a physical interaction between Panx1 and P2X1 in human platelets [123]. In this study, however, chemical inhibition of Panx1 with the non-specific blockers Pbn and mefloquine (Mfq), or with the specific 10Panx1 peptides, decreased ATP release from platelets and their aggregative capacities in response to collagen but not to two other agonists, i.e., ADP and arachidonic acid (Figure 5). These results were confirmed using platelets isolated from Panx1−/− mice [123]. In addition, a similar inhibition of collagen-induced ATP release and platelet aggregation was observed after pre-incubation of human platelets with the commonly-used food dye Brilliant Blue FCF (Figure 5), which has been shown to inhibit Panx1 channel function in a detailed electrophysiological study [124,125]. Mechanistically, the authors dissected in a series of experiments that collagen-induced activation of GPVI receptors resulted in Panx1 phosphorylation by Src kinase and subsequent opening of the Panx1 channels. Then, ATP would pass through the Panx1 channel towards the extracellular space leading to autocrine/paracrine activation of P2X1 receptors and finally platelet aggregation (Figure 5) [123]. The involvement of Panx1 in collagen-induced platelet aggregation was further supported by the finding that a single nucleotide polymorphism (SNP) in the human Panx1 gene, i.e., Panx1 400A>C (rs1138800) encoding for a gain-of-function channel, was associated with increased platelet reactivity to collagen (but not to arachidonic acid and ADP) in healthy subjects [123]. This genotype–phenotype relation was further underscored by a phenotype–genotype relation in a small cohort of patients with an extreme platelet phenotype. Indeed, the gain-of-function Panx1-400C polymorph was more frequently found in patients displaying platelet hyper-reactivity than in those showing a hypo-reactive phenotype [123]. Moving from healthy volunteers to a cohort of stable cardiovascular patients resulted unfortunately in loss of the association between the Panx1 SNP and collagen-induced platelet aggregation [126]. However, it is to be kept in mind that cardiovascular patients compared with healthy controls take different medication including anti-platelet drugs that may blur any fine-tuning effect of the gain-of-function mutation induced by Panx1-400C. In addition, it was noted by the authors that the allelic frequency of the Panx1-400C allele was significantly different in the cardiovascular patient population as compared to the healthy volunteer cohort (55.5% versus 46.9%, respectively), suggesting that inclusion criteria of the Antiplatelet Drug Resistances and Ischemic Events (ADRIE) study might have favored the recruitment of stable cardiovascular patients with a Panx1-400C allele and justifies clinical investigations towards an association between the Panx1-400A>C genetic variant and acute ischemic athero-thrombotic disease. Altogether, the selective involvement of Panx1 channels in collagen-induced platelet aggregation makes this channel an attractive new target for platelet inhibition in the context of athero-thrombosis.
Figure 5. Panx1- and Cx-dependent mechanisms leading to platelet aggregation. Upon GPVI binding to collagen, Src phosphorylation occurs, which permits opening of Panx1 channels and ATP release from platelets. ATP activates P2X$_1$ purinergic receptors, enhancing intracellular calcium concentration and therefore platelet activation and aggregation. Apart from classical anti-platelet drugs targeting signaling pathways linked to ADP and thromboxane A2 (TxA$_2$) receptors, Panx1 inhibitors (FDA approved compounds are indicated in bold) mefloquine (Mfq), probenecid (Pbn), carbenoxolone (Cbx), Brilliant blue FCF and the specific peptide $^{10}$Panx1 have demonstrated inhibitory effects on collagen-induced aggregation (see also Table 1). The role of Cxs in platelet aggregation remains to be further clarified. Two pathways are thought to play a role in platelet aggregation. The first one would occur after stable platelet contact is established, allowing formation of gap junctions and cAMP trafficking between adjacent platelets. cAMP has a regulatory role, inhibiting further platelet aggregation and thrombus growth. The second mechanism would involve inhibition of Cx hemichannels, resulting in diminution of the aggregation response through an as yet undefined pathway. It has been proposed, but not yet proven, that Cx hemichannels may act in a similar fashion as Panx1, thus activating P2X$_1$ receptors via the release of ATP from intracellular space.

3.2. Connexins and Platelet Aggregation

Given their essential role in adhesion of epithelial and inflammatory cells [127–130], the concept that Cxs could participate in mechanisms linked to platelet adhesion, and maybe even aggregation, raised growing interest. The discovery in the 1980s that gap junctions were formed between stromal cells and hematopoietic cells, both in bone marrow tissue and cell culture, suggested that Cxs may be present at the surface of leukocytes and possibly also platelets [131–133]. As a confirmation of this possibility, the mRNA of 16 Cxs were found more than 20 years later in megakaryocytes, among which Cx37, Cx40 and Cx62 showed the highest expression patterns [134]. Some other studies reported the expression of several Cxs in platelets including Cx32, Cx37, Cx40 and Cx43 [134–136]. Formation of functional gap junction channels in platelet aggregates was demonstrated by several techniques allowing the tracking of fluorescent dyes (neurobiotin and calcein) that diffuse from one platelet to another [134,135]. Interestingly, blocking or deleting Cx37 prevented the diffusion of this dye. Although Cx32 and Cx43 mRNA have been found in platelets, functional studies on platelet aggregation and thrombus formation are only performed for Cx37 and Cx40. The first study reported in 2011 that Cx37 deletion in mice increased platelet aggregation in response to collagen, thrombin and ADP. Importantly, increased platelet aggregation responses were also observed when a Cx37 mimetic blocking peptide was used to mimic the effects of the knockout in vitro [135]. A subsequent
series of experiments let the authors propose that Cx37 forms functional gap junction channels during platelet activation when a stable contact is established, allowing for the diffusion of cAMP from one platelet to another (Figure 5). Through the inhibitory effects of cAMP, further platelet recruitment was suppressed and thrombus growth inhibited. A second group extended the function of Cxs in platelets to hemichannels. They observed that deletion of Cx37 reduced fibrinogen binding as well as granule secretion from platelets even when there was no physical contact between platelets [134], suggesting hemichannel involvement. Moreover, blocking or deleting Cx40 in platelets also decreased α-granule secretion, as indicated by reduced expression of P-selectin [136]. Finally, blocking Cx37 with the specific inhibitor \( \text{Gap27} \) in Cx40−/− murine platelets and inhibiting Cx40 with the blocker \( \text{Gap27} \) in Cx37−/− platelets further increased aggregation responses, suggesting that the two Cx hemichannels operate independently from each other [136].

It would be interesting to design experiments that can unequivocally distinct the role of Cx37 hemichannels and gap junction channels in platelet aggregation since it appears that mechanisms involving both types of Cx37 channels are able to interfere somewhere in the platelet aggregation cascade. The way that Cx37 hemichannels participate in platelet activation may be closely related to the manner Panx1 channels regulate platelet function. Cx37 hemichannel opening could allow for the release of ATP from activated platelets, which would then act in an autocrine/paracrine fashion on ionotropic P2X\(_1\) receptors to enhance calcium influx and elevate the level of activation of the platelets (Figure 5). In contrast to Panx1 channels, however, no direct interaction between Cx37 and P2X\(_1\) has been demonstrated yet. Moreover, the mechanism of Cx37 hemichannel opening in the presence of a relatively elevated extracellular calcium concentration in blood, at which Cx37 hemichannels are normally closed, remains to be established [137].

4. “Drug-Ability” of Panx-Cx Targets

Nowadays, the two major anti-platelet drugs prescribed to cardiovascular patients are aspirin and P2Y\(_{12}\) inhibitors (clopidogrel, prasugrel, ticagrelor), which respectively target the TxA\(_2\) and ADP platelet signaling pathways (Figure 5). The use of widely-targeting drugs remains however associated with increased risk of hemorrhage and recurrent ischemic events [138], and the need to find selective-targeting modulators of platelet function is still of importance. Targeting Panx1 channels and possibly Cx channels when the above-described research questions are solved may represent a new potential direction. The following paragraph reviews known pharmacological inhibitors of Panx1 and their potential or proven effects on platelet aggregation (Table 1 and Figure 5).

First, Cbx, a derivative of enoxolone (or glycyrrhetic acid), is an FDA-approved drug used mainly for the treatment of gastric ulcers [139]. It has recently been shown that inhibiting Panx1 with Cbx reduced cancer metastasis in mice [140]. Moreover, Cbx has been shown to inhibit platelet aggregation induced by low doses of collagen (Figure 5) [122]. However, Cbx therapy has been shown to have significant adverse effects such as sodium retention and hypokalaemia [141]. Despite its promising and potent effects on Panx1, Cbx exhibits significant inhibiting effects on Cx channels and may thus be considered non-specific [142].

A second candidate is flufenamic acid, a derivative of fenamate, which has been shown to act as an inhibitor of Panx1 channels [143], although its specificity for Panx over Cxs is still not clear. Flufenamic acid is an inhibitor of the cyclooxygenase pathway and consideration to use this drug to inhibit Panx1 in platelets is no longer valid since a recent study showed that it abolished platelet inhibition by aspirin in humans [144]. Moreover, the use of this drug caused gastrointestinal adverse effects [145].

Mfq, a 4-quinolinemethanol, is a derivative of quinine used as a drug for malaria [146] and a known Panx1 channel blocker. Both quinine and Mfq have been shown to inhibit Panx1 channels, but Mfq is more effective with an IC\(_{50}\) of 50 nM [147]. Data on the specificity of both compounds for Panx channels are sparse. The inhibitory effect of quinine on platelet aggregation has been proven some years ago [148] and Mfq was recently shown to inhibit human platelet aggregation and ATP release
induced by collagen (Figure 5) [123]. However, the prescription of Mfq is now strongly discouraged as studies have evidenced an association between the use of this drug and severe psychiatric side effects such as anxiety, paranoia, psychosis and anterograde amnesia [149].

Pbn is another candidate compound that is an inhibitor of inorganic acid transporters in many organs, including the kidneys, and is principally used in the treatment of chronic gout and as an additive to increase the levels of antibiotics in the blood [150]. The inhibitory effect of Pbn on platelet aggregation became evident for the first time in the 1990s [151]. In fact, Pbn was reported to inhibit platelet aggregation by affecting cytosolic calcium levels and impeding leukotriene C4 exit [152,153]. However, the discovery that Pbn effects involve a Panx1-dependent mechanism has only been demonstrated recently in two studies showing that pre-treating human platelets with Pbn reduced calcium influx, ATP release as well as aggregation responses (Figure 5) [122,123]. Nevertheless more detailed studies on the potential use of Pbn as an anti-aggregation compound will be needed, as it has been described in a case report that combination treatment with oseltamivir and Pbn induced thrombocytopenia [154].

| Compound’s Name   | Clinical Applications                      | Effects on Platelet Aggregation                        | Possible Side Effects                     |
|-------------------|--------------------------------------------|------------------------------------------------------|------------------------------------------|
| Carbenoxolone     | Gastric ulcer [139]                        | Reduces collagen-induced aggregation [122]            | Sodium retention, hypokalaemia [141]     |
| Flufenamic acid   | NA ¹                                       | Reduces aggregation via COX inhibition [144]          | Aspirin antagonism [144], GI ² disturbances [145] |
| Mefloquine        | Malaria [146]                              | Reduces collagen-induced aggregation [123]            | Psychiatric diseases [149]               |
| Probencid         | Gout; Adjuvant for antibiotics [150]       | Inhibits aggregation [122,123,152,153]                | Thrombocytopenia [154]                   |
| Brilliant blue FCF| NA                                         | Reduces collagen-induced aggregation [125]            | NA                                       |
| ¹⁰Panx1 peptide   | NA                                         | Reduces collagen-induced aggregation [123]            | NA                                       |
| TAT-Panx1₃₀⁸      | NA                                         | NA                                                   | NA                                       |

¹ NA (non applicable); ² GI (gastrointestinal).

Finally, the food dye Brilliant Blue FCF, a triarylmethane dye, has been shown in 2013 to act as a specific inhibitor of Panx1 [124]. Due to its strong similarity with the purinergic receptor inhibitor Brilliant Blue G, Brilliant Blue FCF was first thought to act as a chemical blocker of the purinergic receptor P2X₇, which is known to interact with Panx1 during inflammasome activation [155,156]. It was then demonstrated that no effect of Brilliant Blue FCF was observed, even when high concentrations were used, and that the dye had a specific action on Panx1 with an IC₅₀ of 0.27 µM [124]. Moreover, Brilliant Blue FCF does not seem to affect Cx channels, which makes the dye a first choice inhibitor in experimental studies as compared to Cbx, Mfq or Pbn [124]. In a recent study, a relatively high concentration of Brilliant Blue FCF was shown to selectively inhibit collagen-induced aggregation of human washed platelets (Figure 5) [125]. Interestingly, the selectivity for collagen-dependent responses and the non-toxicity of the dye on platelets was underscored by the fact that the dye did not affect the aggregation response to arachidonic acid in these platelets [125]. Additional studies should determine a possible influence of Brilliant Blue FCF on the aggregation induced by other agonists in vitro and on thrombosis in vivo in animal models. Due to its low oral absorption, there are only a few reports on toxicity related to Brilliant Blue FCF, and no evident toxic or carcinogenic effects have been observed in animal models [157,158]. Moreover, low doses of Brilliant Blue FCF are apparently well tolerated in humans as this dye is commonly used in multiple blue food products.

The major issue with Panx1 blockers being their specificity (for Panxs over Cxs), mimetic peptides have been developed for research purposes. ¹⁰Panx1 peptides have been shown to selectively reduce collagen-induced aggregation of human washed platelets by about 40%, while a scrambled peptide
did not display any effects. Similarly, no effects were seen on the aggregation response induced by other agonists (Figure 5) [123].\textsuperscript{10} Panx1 is a mimetic peptide of the first EL domain of Panx1 that impedes the passage of small molecules and ATP through the channel [159]. Although controversial and needing further confirmation in other expression systems, we should keep in mind that\textsuperscript{10} Panx1 was shown to inhibit the lens-specific Cx46 hemichannel currents in oocytes to about the same extent as Panx1 currents [160]. There is, however, a more promising development involving peptide-based inhibition of Panx1 channels that may also be suitable for platelets [161–163]. The peptide contains a TAT sequence allowing its entry into the cell. Once in the cytoplasm, the peptide recognizes the binding site (Y308) for Src proteins on Panx1 and avoids the phosphorylation of the protein, thus inhibiting channel opening. The efficacy of this strategy has been demonstrated in a study where inhibition of NMDA-dependent Panx1 phosphorylation by Src was blocked by the TAT-tagged peptide (TAT-Panx1\textsubscript{308}) and conferred a significant neuroprotection before or two hours after ischemic stroke in adult rats [161]. This peptide-based strategy requires urgent testing in the context of platelet aggregation as it may represent a new manner to selectively modulate collagen-induced platelet aggregation that also involves Src-dependent phosphorylation of Panx1 channels [123]. Indeed, research towards compounds selectively inhibiting Panx1 channels is only in its infancy but holds fair promise for the development of selective inhibitors of collagen-induced platelet aggregation.

5. Conclusions

The role of Cxs and Panx1 in platelet aggregation is an exciting field of actual research, which holds promise for targeted drug development in order to prevent thrombotic diseases. Future investigations should provide further detailed insight into the molecular mechanisms linking Cx hemichannels or gap junctions to platelet reactivity. Our mechanistic insight into the role of Panx1 channels in platelet reactivity is rather advanced and already allows for a careful search towards new pharmacological strategies aiming at reducing ischemic events in cardiovascular patients without increasing the risk of bleeding.

Acknowledgments: The authors would like to thank Issa Kutkut for critical comments on the manuscript. This work was supported by grants from the Swiss National Science Foundation (310030_162579/1 to Brenda R. Kwak and 310030_162567 to Pierre Fontana) and the Swiss Heart Foundation (to Brenda R. Kwak and Pierre Fontana).

Author Contributions: Filippo Molica, Florian B. Stierlin, Pierre Fontana and Brenda R. Kwak contributed to the writing of the paper.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AMPA \textsuperscript{\textcopyright}-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate

NMDA N-methyl-D-aspartate

GP Glycoprotein

vWF Von Willebrand

PAR Protease-activated receptor

cAMP Cyclic adenosine monophosphate

FcR Fc receptor

ITAM Immunoreceptor tyrosine-based activation motif

Syk Spleen tyrosine kinase

PLCy2 Phospholipase Cy2

P13 Phosphoinositide-3

IP3 Inositol 1,4,5-trisphosphate

DAG Diacylglycerol

PKC Protein kinase C

TxA\textsubscript{2} Thromboxane A\textsubscript{2}

FIP3 Phosphatidylinositol 3,4,5-trisphosphate
References

1. Kumar, V.; Abbas, A.K.; Aster, J.C.; Cotran, R.S.; Robbins, S.L. *Robbins and Cotran Pathologic Basis of Disease (Robbins Pathology)*, 9th ed.; Elsevier: Amsterdam, The Netherlands, 2014; p. 1391.

2. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. *Nature* 2011, 473, 317–325. [CrossRef] [PubMed]

3. Ross, R. Atherosclerosis—An inflammatory disease. *N. Engl. J. Med.* 1999, 340, 115–126. [CrossRef]

4. Back, M.; Weber, C.; Lutgens, E. Regulation of atherosclerotic plaque inflammation. *J. Intern. Med.* 2015, 278, 462–482. [CrossRef] [PubMed]

5. Lahoute, C.; Herbin, O.; Mallat, Z.; Tedgui, A. Adaptive immunity in atherosclerosis: Mechanisms and future therapeutic targets. *Nat. Rev. Cardiol.* 2011, 8, 348–358. [CrossRef] [PubMed]

6. Yla-Herttuala, S.; Bentzon, J.F.; Daemen, M.; Falk, E.; Garcia-Garcia, H.M.; Herrmann, J.; Hoefer, I.; Jauhiainen, S.; Jukema, J.W.; Krams, R.; et al. Stabilization of atherosclerotic plaques: An update. *Eur. Heart J.* 2013, 34, 3251–3258. [CrossRef] [PubMed]

7. Newby, A.C. Metalloproteinases and vulnerable atherosclerotic plaques. *Trends Cardiovasc. Med.* 2007, 17, 253–258. [CrossRef] [PubMed]

8. Edfeldt, K.; Swedenborg, J.; Hansson, G.K.; Yan, Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. *Circulation* 2002, 105, 1158–1161. [PubMed]

9. Berna-Erro, A.; Jardin, I.; Smani, T.; Rosado, J.A. Regulation of platelet function by Orai, STIM and TRP. *Adv. Exp. Med. Biol.* 2016, 898, 157–181. [PubMed]

10. Mahaut-Smith, M.P. The unique contribution of ion channels to platelet and megakaryocyte function. *J. Thromb. Haemost.* 2012, 10, 1722–1732. [CrossRef] [PubMed]

11. Nuyttens, B.P.; Thijs, T.; Deckmyn, H.; Broos, K. Platelet adhesion to collagen. *Thromb. Res.* 2011, 127 (Suppl. S2), S26–S29. [CrossRef]

12. Ruggeri, Z.M. Von willebrand factor: Looking back and looking forward. *Thromb. Haemost.* 2007, 98, 55–62. [CrossRef] [PubMed]

13. Ulrichs, H.; Udvardy, M.; Lenting, P.J.; Pareyn, I.; Vandeputte, N.; Vanhoorelbeke, K.; Deckmyn, H. Shielding of the a1 domain by the D’D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. *J. Biol. Chem.* 2006, 281, 4699–4707. [CrossRef] [PubMed]
35. Kunicki, T.J.; Nugent, D.J.; Staats, S.J.; Orchekowski, R.P.; Wayner, E.A.; Carter, W.G. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein la-IIa complex. *J. Biol. Chem.* 1988, 263, 4516–4519. [PubMed]

36. Sixma, J.J.; van Zanten, G.H.; Huizinga, E.G.; van der Plas, R.M.; Verkley, M.; Wu, Y.P.; Gros, P.; de Groot, P.G. Platelet adhesion to collagen: An update. *Thromb. Haemost.* 1997, 78, 434–438. [PubMed]

37. Elices, M.J.; Hemler, M.E. The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. *Proc. Natl. Acad. Sci. USA* 1989, 86, 9906–9910. [CrossRef] [PubMed]

38. Emsley, J.; Knight, C.G.; Farndale, R.W.; Barnes, M.J.; Liddington, R.C. Structural basis of collagen recognition by integrin α2β1. *Cell* 2000, 101, 47–56. [CrossRef]

39. Calderwood, D.A.; Fujioka, Y.; de Pereda, J.M.; Garcia-Alvarez, B.; Nakamoto, T.; Margolis, B.; McGlade, C.J.; Liddington, R.C.; Ginsberg, M.H. Integrin β cytoplasmic domain interactions with phosphorytrosine-binding domains: A structural prototype for diversity in integrin signaling. *Proc. Natl. Acad. Sci. USA* 2003, 100, 2272–2277. [CrossRef] [PubMed]

40. Banno, A.; Ginsberg, M.H. Integrin activation. *Biochem. Soc. Trans.* 2008, 36, 229–234. [CrossRef] [PubMed]

41. Wegener, K.L.; Partridge, A.W.; Han, J.; Pickford, A.R.; Liddington, R.C.; Ginsberg, M.H.; Campbell, I.D. Structural basis of integrin activation by talin. *Cell* 2007, 128, 171–182. [CrossRef] [PubMed]

42. Tadokoro, S.; Shattil, S.J.; Eto, K.; Tai, V.; Liddington, R.C.; de Pereda, J.M.; Ginsberg, M.H.; Calderwood, D.A. Talin binding to integrin β tails: A final common step in integrin activation. *Science* 2003, 302, 103–106. [CrossRef] [PubMed]

43. Jung, S.M.; Moroi, M. Activation of the platelet collagen receptor integrin α2β1: Its mechanism and participation in the physiological functions of platelets. *Trends Cardiovasc. Med.* 2000, 10, 285–292. [CrossRef]

44. Inoue, O.; Suzuki-Inoue, K.; Dean, W.L.; Frampton, J.; Watson, S.P. Integrin α2β1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCγ2. *J. Cell Biol.* 2003, 160, 769–780. [CrossRef] [PubMed]

45. Herr, A.B.; Farndale, R.W. Structural insights into the interactions between platelet receptors and fibrillar collagen. *J. Biol. Chem.* 2009, 284, 19781–19785. [CrossRef] [PubMed]

46. Lee, J.O.; Rieu, P.; Arnaout, M.A.; Liddington, R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). *Cell* 1995, 80, 631–638. [CrossRef]

47. Kamiguti, A.S.; Hay, C.R.; Zuzel, M. Inhibition of collagen-induced platelet aggregation as the result of cleavage of α2β1-integrin by the snake venom metalloproteinase jararhagin. *Biochem. J.* 1996, 320 Pt 2, 635–641. [CrossRef] [PubMed]

48. Kamiguti, A.S.; Markland, F.S.; Zhou, Q.; Laing, G.D.; Theakston, R.D.; Zuzel, M. Proteolytic cleavage of the β1 subunit of platelet α2β1 integrin by the metalloproteinase jararhagin compromises collagen-stimulated phosphorylation of pp72syk. *J. Biol. Chem.* 1997, 272, 32599–32605. [CrossRef] [PubMed]

49. Watson, S.P. Collagen receptor signaling in platelets and megakaryocytes. *Thromb. Haemost.* 1999, 82, 365–376. [PubMed]

50. Knight, C.G.; Morton, L.F.; Onley, D.J.; Peachey, A.R.; Messent, A.J.; Smethurst, P.A.; Tuckwell, D.S.; Farndale, R.W.; Barnes, M.J. Identification in collagen type I of an integrin α2β1-binding site containing an essential ger sequence. *J. Biol. Chem.* 1998, 273, 33287–33294. [CrossRef] [PubMed]

51. Rudd, C.E.; Janssen, O.; Cai, Y.C.; da Silva, A.J.; Raab, M.; Prasad, K.V. Two-step TCR/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. *J. Biol. Chem.* 2000, 276, 225–234. [CrossRef] [PubMed]

52. Farndale, R.W.; Sixma, J.J.; Barnes, M.J.; de Groot, P.G. The role of collagen in thrombosis and hemostasis. *J. Thromb. Haemost.* 2004, 2, 561–573. [CrossRef] [PubMed]

53. Coller, B.S.; Shattil, S.J. The GPIIb/IIIa (integrin αIIbβ3) odyssey: A technology-driven saga of a receptor with twists, turns, and even a bend. *Blood* 2008, 112, 3011–3025. [CrossRef] [PubMed]

54. Shattil, S.J.; Kim, C.; Ginsberg, M.H. The final steps of integrin activation: The end game. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 288–300. [CrossRef] [PubMed]

55. Savage, B.; Shattil, S.J.; Ruggeri, Z.M. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin αIIbβ3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. *J. Biol. Chem.* 1992, 267, 11300–11306. [PubMed]

56. Wagner, C.L.; Mascelli, M.A.; Neblock, D.S.; Weisman, H.F.; Coller, B.S.; Jordan, R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. *Blood* 1996, 88, 907–914. [PubMed]
57. Shattil, S.J.; Kashiwagi, H.; Pampori, N. Integrin signaling: The platelet paradigm. *Blood* 1998, 91, 2645–2657. [PubMed]

58. Weisel, J.W.; Nagaswami, C.; Vilaire, G.; Bennett, J.S. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. *J. Biol. Chem.* 1992, 267, 16637–16643. [PubMed]

59. Li, Z.; Delaney, M.K.; O’Brien, K.A.; Du, X. Signaling during platelet adhesion and activation. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 2341–2349. [CrossRef] [PubMed]

60. Liu, S.; Calderwood, D.A.; Ginsberg, M.H. Integrin cytoplasmic domain-binding proteins. *J. Cell Sci.* 2000, 113 Pt 20, 3563–3571. [PubMed]

61. Ma, Y.Q.; Qin, J.; Wu, C.; Plow, E.F. Kindlin-2 (Mig-2): A co-activator of β3 integrins. *J. Cell Biol.* 2008, 181, 439–446. [CrossRef] [PubMed]

62. Bos, J.L. Linking rap to cell adhesion. *Curr. Opin. Cell Biol.* 2005, 17, 123–128. [CrossRef] [PubMed]

63. Lee, H.S.; Lim, C.J.; Puzon-Mclaughlin, W.; Shattil, S.J.; Ginsberg, M.H. RIAM activates integrins by linking talin to ras GTPase membrane-targeting sequences. *J. Biol. Chem.* 2009, 284, 5119–5127. [CrossRef] [PubMed]

64. Chrzanoswska-Wodnicka, M.; Smyth, S.S.; Schoenwaelder, S.M.; Fischer, T.H.; White, G.C., 2nd. Rap1b is required for normal platelet function and hemostasis in mice. *J. Clin. Invest.* 2005, 115, 680–687. [CrossRef] [PubMed]

65. Leisner, T.M.; Wencel-Drake, J.D.; Wang, W.; Lam, S.C. Bidirectional transmembrane modulation of integrin αIIbβ3 conformations. *J. Biol. Chem.* 1999, 274, 12945–12949. [CrossRef] [PubMed]

66. Ginsberg, M.H.; Partridge, A.; Shattil, S.J. Integrin regulation. *Curr. Opin. Cell Biol.* 2005, 17, 509–516. [CrossRef] [PubMed]

67. Shattil, S.J.; Newman, P.J. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. *Blood* 2004, 104, 1606–1615. [CrossRef] [PubMed]

68. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. *Cell* 2002, 110, 673–687. [CrossRef]

69. Gong, H.; Shen, B.; Flevaris, P.; Chow, C.; Lam, S.C.; Voyno-Yasenetskaya, T.A.; Kozasa, T.; Du, X. G protein-coupled receptor kinase 2 promotes membrane protrusion and polarity. *J. Biol. Chem.* 2010, 285, 29426–29430. [CrossRef] [PubMed]

70. Thomas, S.M.; Brugge, J.S. Cellular functions regulated by Src family kinases. *Annu. Rev. Cell Dev. Biol.* 1997, 13, 513–609. [CrossRef] [PubMed]

71. Law, D.A.; DeGuzman, F.R.; Heiser, P.; Ministri-Madrid, K.; Killeen, N.; Phillips, D.R. Integrin cytoplasmic domain regulates αIIbβ3 integrin conformation and mediates integrin “outside-in” signaling. *Science* 2010, 327, 340–343. [CrossRef] [PubMed]

72. Anthis, N.J.; Haling, J.R.; Oxley, C.L.; Memo, M.; Wegener, K.L.; Lim, C.J.; Ginsberg, M.H.; Campbell, I.D. β integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. *J. Biol. Chem.* 2009, 284, 36700–36710. [CrossRef] [PubMed]

73. Xi, X.; Flevaris, P.; Stojanovic, A.; Chishti, A.; Phillips, D.R.; Lam, S.C.; Du, X. Tyrosine phosphorylation of the integrin β3 subunit regulates β3 cleavage by calpain. *J. Biol. Chem.* 2006, 281, 29426–29430. [CrossRef] [PubMed]

74. Kunapuli, S.P.; Ding, Z.; Dorsam, R.T.; Kim, S.; Murugappan, S.; Quinton, T.M. Adp receptors—Target for developing antithrombotic agents. *Curr. Pharm. Des.* 2003, 9, 2303–2316. [CrossRef] [PubMed]

75. Arthur, W.T.; Petch, L.A.; Burridge, K. Integrin engagement suppresses rhoa activity via a c-Src-dependent mechanism. *Curr. Biol.* 2000, 10, 719–722. [CrossRef]

76. Arthur, W.T.; Burridge, K. Rhoa inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. *Mol. Biol. Cell* 2001, 12, 2711–2720. [CrossRef] [PubMed]

77. Öbergfell, A.; Eto, K.; Mocsai, A.; Buensucceso, C.; Moores, S.L.; Brugge, J.S.; Lowell, C.A.; Shattil, S.J. Coordinate interactions of Csk, Src, and Syk kinases with αIIbβ3 initiate integrin signaling to the cytoskeleton. *J. Cell Biol.* 2002, 157, 265–275. [CrossRef] [PubMed]

78. Boylan, B.; Gao, C.; Rathore, V.; Gill, J.C.; Newman, D.K.; Newman, P.J. Identification of FcyRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets. *Blood* 2008, 112, 2780–2786. [CrossRef] [PubMed]

79. Hechler, B.; Gachet, C. Purinergic receptors in thrombosis and inflammation. *Arterioscler. Thromb. Vasc. Biol.* 2015, 35, 2307–2315. [CrossRef] [PubMed]
80. Jin, J.; Daniel, J.L.; Kunapuli, S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 1998, 273, 2030–2034. [CrossRef] [PubMed]

81. Gachet, C. Regulation of platelet functions by P2 receptors. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 277–300. [CrossRef] [PubMed]

82. Hourani, S.M.; Cusack, N.J. Pharmacological receptors on blood platelets. Pharmacol. Rev. 1991, 43, 243–298. [PubMed]

83. Andre, P.; Prasad, K.S.; Denis, C.V.; He, M.; Papalia, J.M.; Hynes, R.O.; Phillips, D.R.; Wagner, D.D. CD40L-induced platelet ADP receptor activates G12 proteins. Biochem. J. 1995, 312 Pt 3, 775–779. [CrossRef] [PubMed]

84. Paul, B.Z.; Jin, J.; Kunapuli, S.P. Molecular mechanism of thromboxane A2-induced platelet aggregation. Essential role for P2TAC and α2A receptors. J. Biol. Chem. 1999, 274, 29018–29014. [CrossRef] [PubMed]

85. Ohlmann, P.; Laugwitz, K.L.; Nurnberg, B.; Spicher, K.; Schultz, G.; Cazenave, J.P.; Gachet, C. The human platelet ADP receptor activates G12 proteins. Biochem. J. 1995, 312 Pt 3, 775–779. [CrossRef] [PubMed]

86. Prevost, N.; Woulfe, D.S.; Jiang, H.; Kunapuli, S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 1998, 273, 2030–2034. [CrossRef] [PubMed]

87. Swieringa, F.; Kuijpers, M.J.; Heemskerk, J.W.; van der Meijden, P.E. Targeting platelet receptor function in cardiovascular diseases. Vegetat. Physiology 2009, 41, 2030–2034. [CrossRef] [PubMed]

88. Zahid, M.; Mangin, P.; Loyau, S.; Hechler, B.; Billiard, P.; Gachet, C.; Jandrot-Perrus, M. The future of glycoprotein VI as an anti-thrombotic target. J. Thromb. Haemost. 2012, 10, 2418–2427. [CrossRef] [PubMed]

89. Molica, F.; Meens, M.J.; Morel, S.; Kwak, B.R. Mutations in connexin genes and disease. Pharmacol. Rev. 2006, 46, 277–300. [CrossRef] [PubMed]

90. Kelly, J.J.; Simek, J.; Laird, D.W. Mechanisms linking connexin mutations to human diseases. Cell Tissue Res. 2015, 360, 701–721. [CrossRef] [PubMed]

91. Abascal, F.; Zardoya, R. Evolutionary analyses of gap junction protein families. Biochim. Biophys. Acta 2013, 1828, 1–14. [CrossRef] [PubMed]

92. Laird, D.W. Life cycle of connexins in health and disease. Biochem. J. 2006, 394, 527–543. [CrossRef] [PubMed]

93. Thevenin, A.F.; Kowal, T.J.; Fong, J.T.; Kells, R.M.; Fisher, C.G.; Falk, M.M. Proteins and mechanisms regulating gap-junction assembly, internalization, and degradation. Physiology 2013, 28, 93–116. [CrossRef] [PubMed]

94. Koval, M.; Molina, S.A.; Burt, J.M. Mix and match: Investigating heteromeric and heterotypic gap junction channels in model systems and native tissues. FEBS Lett. 2014, 588, 1193–1204. [CrossRef] [PubMed]

95. Patel, D.; Zhang, X.; Veenstra, R.D. Connexin hemichannel and pannexin channel electrophysiology: How do they differ? FEBS Lett. 2014, 588, 1372–1378. [CrossRef] [PubMed]

96. Saez, J.C.; Leybaert, L. Hunting for connexin hemichannels. FEBS Lett. 2014, 588, 1205–1211. [CrossRef] [PubMed]

97. Nielsen, M.S.; Axelsen, L.N.; Sorgen, P.L.; Verma, V.; Delmar, M.; Holstein-Rathlou, N.H. Gap junctions. Compr. Physiol. 2012, 2, 1981–2035. [PubMed]

98. Solan, J.L.; Lampe, P.D. Connexin43 phosphorylation: Structural changes and biological effects. Biochem. J. 2009, 419, 261–272. [CrossRef] [PubMed]

99. Begandt, D.; Good, M.E.; Keller, A.S.; DeLalio, L.J.; Rowley, C.; Isakson, B.E.; Figueroa, X.F. Pannexin channel and connexin hemichannel expression in vascular function and inflammation. BMC Cell. Biol. 2017, 18, 2. [CrossRef] [PubMed]

100. Laird, D.W. The gap junction proteome and its relationship to disease. Trends Cell. Biol. 2010, 20, 92–101. [CrossRef] [PubMed]

101. Aguillo-Pascual, E.; Cerrone, M.; Delmar, M. Arrhythmogenic cardiomyopathy and Brugada syndrome: Diseases of the connexome. FEBS Lett. 2014, 588, 1322–1330. [CrossRef] [PubMed]

102. Pfenniger, A.; Wohlwend, A.; Kwak, B.R. Mutations in connexin genes and disease. Eur. J. Clin. Investig. 2011, 41, 103–116. [CrossRef] [PubMed]

103. Panchin, Y.; Kelmanson, I.; Matz, M.; Lukyanov, K.; Usman, N.; Lukyanov, S. A ubiquitous family of putative gap junction molecules. Curr. Biol. 2000, 10, R473–R474. [CrossRef]
104. Shestopalov, V.I.; Panchin, Y. Pannexins and gap junction protein diversity. *Cell Mol. Life Sci.* 2008, 65, 376–394. [CrossRef] [PubMed]

105. Bond, S.R.; Naus, C.C. The pannexins: Past and present. *Front. Physiol.* 2014, 5, 58. [CrossRef] [PubMed]

106. Dahl, G.; Muller, K.J. Innexin and pannexin channels and their signaling. *FEBS Lett.* 2014, 588, 1396–1402. [CrossRef] [PubMed]

107. Penuela, S.; Harland, L.; Simek, J.; Laird, D.W. Pannexin channels and their links to human disease. *Biochem. J.* 2014, 461, 371–381. [CrossRef] [PubMed]

108. Boassa, D.; Ambrosi, C.; Qiu, F.; Dahl, G.; Gaietta, G.; Sosinsky, G. Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. *J. Biol. Chem.* 2007, 282, 31733–31743. [CrossRef] [PubMed]

109. Esseltine, J.L.; Laird, D.W. Regulation of pannexin channels by post-translational modifications. *FEBS Lett.* 2014, 588, 1411–1415. [CrossRef] [PubMed]

110. Bruzzone, R.; Hormuzdi, S.G.; Barbe, M.T.; Herb, A.; Monyer, H. Pannexins, a family of gap junction proteins expressed in brain. *Proc. Natl. Acad. Sci. USA* 2003, 100, 13644–13649. [CrossRef] [PubMed]

111. Sosinsky, G.E.; Boassa, D.; Dermietzel, R.; Duffy, H.S.; Laird, D.W.; MacVicar, B.; Naus, C.C.; Penuela, S.; Scemes, E.; Spray, D.C.; et al. Pannexin channels are not gap junction hemichannels. *Channels* 2011, 5, 193–197. [CrossRef] [PubMed]

112. Penuela, S.; Simek, J.; Thompson, R.J. Pannexin channels and ischaemia. *FEBS Lett.* 2014, 588, 380, 239–244. [CrossRef] [PubMed]

113. Bao, L.; Locovei, S.; Dahl, G. Pannexin membrane channels are mechanosensitive conduits for ATP. *FEBS Lett.* 2004, 572, 65–68. [CrossRef] [PubMed]

114. Locovei, S.; Wang, J.; Dahl, G. Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium. *FEBS Lett.* 2006, 580, 239–244. [CrossRef] [PubMed]

115. Scemes, E. Nature of plasmalemmal functional “hemichannels”. *Biochim. Biophys. Acta* 2012, 1818, 1880–1883. [CrossRef] [PubMed]

116. Kunapuli, S.P.; Dorsam, R.T.; Kim, S.; Quinton, T.M. Platelet purinergic receptors. *Curr. Opin. Pharmacol.* 2003, 3, 175–180. [CrossRef]

117. Adamson, S.E.; Leitinger, N. The role of pannexin1 in the induction and resolution of inflammation. *FEBS Lett.* 2014, 588, 1416–1422. [CrossRef] [PubMed]

118. Meens, M.J.; Kwak, B.R.; Duffy, H.S. Role of connexins and pannexins in cardiovascular physiology. *Cell Mol. Life Sci.* 2015, 72, 2779–2792. [CrossRef] [PubMed]

119. Thompson, R.J. Pannexin channels and ischaemia. *J. Physiol.* 2015, 593, 3463–3470. [CrossRef] [PubMed]

120. Andrews, R.K.; Berndt, M.C. Platelet physiology and thrombosis. *Thromb. Res.* 2004, 114, 447–453. [CrossRef] [PubMed]

121. Gibbins, J.M. Platelet adhesion signalling and the regulation of thrombus formation. *J. Cell Sci.* 2004, 117, 3415–3425. [CrossRef] [PubMed]

122. Taylor, K.A.; Wright, J.R.; Vial, C.; Evans, R.J.; Mahaut-Smith, M.P. Amplification of human platelet activation by surface pannexin-1 channels. *J. Thromb. Haemost.* 2014, 12, 987–998. [CrossRef] [PubMed]

123. Molica, F.; Morel, S.; Meens, M.J.; Denis, J.F.; Bradfield, P.F.; Penuela, S.; Zufferey, A.; Monyer, H.; Imhof, B.A.; Chanson, M.; et al. Functional role of a polymorphism in the pannexin1 gene in collagen-induced platelet aggregation. *Thromb. Haemost.* 2015, 114, 325–336. [CrossRef] [PubMed]

124. Wang, J.; Jackson, D.G.; Dahl, G. The food dye FD&C Blue No. 1 is a selective inhibitor of the ATP release channel Panx1. *J. Gen. Physiol.* 2013, 141, 649–656. [PubMed]

125. Molica, F.; Noll, S.; Fontana, P.; Kwak, B.R. Turbidimetry on human washed platelets: The effect of the pannexin1-inhibitor Brilliant Blue FCF on collagen-induced aggregation. *J. Vis. Exp.* 2017, in press.

126. Stierlin, F.B.; Molica, F.; Naus, C.C.; Kwak, B.R.; Penuela, S.; Zufferey, A.; Monyer, H.; Chanson, M.; et al. Pannexin1 single nucleotide polymorphism and platelet reactivity in a cohort of cardiovascular patients. *Cell Commun. Adhes.* 2017, 114, 29783. [CrossRef] [PubMed]
129. Wong, C.W.; Christen, T.; Roth, I.; Chadjichristos, C.E.; Derouette, J.P.; Foglia, B.F.; Chanson, M.; Goodenough, D.A.; Kvak, B.R. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. *Nat. Med.* 2006, 12, 950–954. [CrossRef] [PubMed]

130. Kameritsch, P.; Pogoda, K.; Pohl, U. Channel-independent influence of connexin 43 on cell migration. *Biochim. Biophys. Acta* 2012, 1818, 1993–2001. [CrossRef] [PubMed]

131. Campbell, F.R. Gap junctions between cells of bone marrow: An ultrastructural study using tannic acid. *Anat. Rec.* 1980, 196, 101–107. [CrossRef] [PubMed]

132. Campbell, F.R. Ultrastructural studies of intercellular contacts (junctions) in bone marrow: A review. *Scan. Electron. Microsc.* 1986, 621–629.

133. Allen, T.D.; Dexter, T.M. Ultrastructural aspects of erythropoietic differentiation in long-term bone marrow culture. *Differentiation* 1982, 21, 86–94. [CrossRef] [PubMed]

134. Vaiyapuri, S.; Jones, C.I.; Sasikumar, P.; Moraes, L.A.; Munger, S.J.; Wright, J.R.; Ali, M.S.; Sage, T.; Kaiser, W.J.; Tucker, K.L.; et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. *Circulation* 2012, 125, 2479–2491. [CrossRef] [PubMed]

135. Derouette, J.P.; Desplantez, T.; Wong, C.W.; Roth, I.; Sugamele, R.; Brisset, A.; Morel, S.; Nolli, S.; Chassot, A.; et al. Connexin 37 limits thrombus propensity by downregulating platelet reactivity. *Circulation* 2011, 124, 930–939. [CrossRef] [PubMed]

136. Creager, M.A. Results of the capri trial: Efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. *Vasc. Med.* 1998, 3, 257–260. [CrossRef] [PubMed]

137. Chavez-Pina, A.E.; Tapia-Alvarez, G.R.; Reyes-Ramirez, A.; Navarrete, A. Carbenoxolone gastroprotective mechanism: Participation of nitric oxide/GMP/KATP pathway in ethanol-induced gastric injury in the rat. *Fundam. Clin. Pharmacol.* 2011, 25, 717–722. [CrossRef] [PubMed]

138. Davies, G.J.; Rhodes, J.; Calcraft, B.J. Complications of carbenoxolone therapy. *Br. J. Med.* 1974, 3, 400–402. [CrossRef] [PubMed]

139. Mitrou, N.; Braam, B.; Cupples, W.A. A gap junction inhibitor, carbenoxolone, induces spatiotemporal dispersion of renal cortical perfusion and impairs autoregulation. *Am. J. Physiol. Heart Circ. Physiol.* 2016, 311, H582–H591. [CrossRef] [PubMed]

140. Bruzzone, R.; Barbe, M.T.; Jakob, N.J.; Monyer, H. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. *J. Neurochem.* 2005, 92, 1033–1043. [CrossRef] [PubMed]

141. Saxena, A.; Balaramnavar, V.M.; Hohlfeld, T.; Saxena, A.K. Drug/drug interaction of common nsais with antiplatelet effect of aspirin in human platelets. *Eur. J. Pharmacol.* 2013, 721, 215–224. [CrossRef] [PubMed]

142. Farrugia, G.; Nitecki, S.; Harty, G.J.; Camilleri, M.; Szurszewski, J.H. The effect of flufenamic acid on gastrointestinal myoelectrical activity and transit time in dogs. *Gut* 1998, 42, 258–265. [CrossRef] [PubMed]

143. Price, R.N.; Nosten, F.; Luxemburger, C.; van Vugt, M.; Phaipun, L.; Chongsuphajaisiddhi, T.; White, N.J. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. *Trans. R. Soc. Trop. Med. Hyg.* 1997, 91, 574–577. [CrossRef]

144. Dahl, G.; Qiu, F.; Wang, J. The bizarre pharmacology of the ATP release channel pannexin1. *Neuropharmacology* 2013, 75, 583–593. [CrossRef] [PubMed]

145. Connellan, J.M.; Deacon, S.; Thurlow, P.J. Changes in platelet function and reactivity induced by quinine in relation to quinine (drug) induced immune thrombocytopenia. *Thromb. Res.* 1991, 61, 501–514. [CrossRef]

146. Ritchie, E.C.; Block, J.; Nevin, R.L. Psychiatric side effects of mefloquine: Applications to forensic psychiatry. *J. Am. Acad. Psychiatry Law* 2013, 41, 224–235. [PubMed]

147. Cunningham, R.F.; Israili, Z.H.; Dayton, P.G. Clinical pharmacokinetics of probenecid. *Clin. Pharmacokinet* 1981, 6, 135–151. [CrossRef] [PubMed]
151. Packham, M.A.; Rand, M.L.; Perry, D.W.; Ruben, D.H.; Kinlough-Rathbone, R.L. Probenecid inhibits platelet responses to aggregating agents in vitro and has a synergistic inhibitory effect with penicillin G. *Thromb. Haemost.* 1996, 76, 239–244. [PubMed]

152. Sjolinder, M.; Tornhamre, S.; Claesson, H.E.; Hydman, J.; Lindgren, J. Characterization of a leukotriene C4 export mechanism in human platelets: Possible involvement of multidrug resistance-associated protein 1. *J. Lipid Res.* 1999, 40, 439–446. [PubMed]

153. Ozaki, Y.; Matsumoto, Y.; Yatomi, Y.; Higashihara, M.; Kariya, T.; Shoji, K. Effects of five anion channel blockers on thrombin- and ionomycin-activated platelet functions. *Biochem. Pharmacol.* 1989, 38, 2147–2152. [PubMed]

154. Raisch, D.W.; Straight, T.M.; Holodnyi, M. Thrombocytopenia from combination treatment with oseltamivir and probenecid: Case report, medwatch data summary, and review of the literature. *Pharmacotherapy* 2009, 29, 988–992. [CrossRef] [PubMed]

155. Poornima, V.; Madhupriya, M.; Kootar, S.; Sujatha, G.; Kumar, A.; Bera, A.K. P2X7 receptor-pannexin 1 hemichannel association: Effect of extracellular calcium on membrane permeabilization. *J. Mol. Neurosci.* 2012, 46, 585–594. [CrossRef] [PubMed]

156. Xu, X.J.; Boumechache, M.; Robinson, L.E.; Marschall, V.; Gorecki, D.C.; Masin, M.; Murrell-Lagnado, R.D. Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1. *J. Cell Sci.* 2012, 125, 3776–3789. [CrossRef] [PubMed]

157. Gettings, S.D.; Blaszcak, D.L.; Roddy, M.T.; Curry, A.S.; McEwen, G.N., Jr. Evaluation of the cumulative (repeated application) eye irritation and corneal staining potential of FD&C Yellow No. 5, FD&C Blue No. 1 and FD&C Blue No. 1 aluminium lake. *Food Chem. Toxicol.* 1992, 30, 1051–1055. [PubMed]

158. Borzelleca, J.F.; Depukat, K.; Hallagan, J.B. Lifetime toxicity/carcinogenicity studies of FD&C Blue No. 1 (Brilliant Blue FCF) in rats and mice. *Food Chem. Toxicol.* 1990, 28, 221–234. [PubMed]

159. Pelegrin, P.; Surprenant, A. Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor. *EMBO J.* 2006, 25, 5071–5082. [CrossRef] [PubMed]

160. Wang, J.; Ma, M.; Locovei, S.; Keane, R.W.; Dahl, G. Modulation of membrane channel currents by gap junction protein mimetic peptides: Size matters. *Am. J. Physiol. Cell Physiol.* 2007, 293, C1112–C1119. [CrossRef] [PubMed]

161. Weilinger, N.L.; Lohman, A.W.; Rakai, B.D.; Ma, E.M.; Bialecki, J.; Maslieieva, V.; Rilea, T.; Bandet, M.V.; Ikuta, N.T.; Scott, L.; et al. Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity. *Nat. Neurosci.* 2016, 19, 432–442. [CrossRef] [PubMed]

162. Billaud, M.; Chiu, Y.H.; Lohman, A.W.; Parpaite, T.; Butcher, J.T.; Muchler, S.M.; DeLalio, L.J.; Artamonov, M.V.; Sandilos, J.K.; Best, A.K.; et al. A molecular signature in the pannexin1 intracellular loop confers channel activation by the α1 adrenoreceptor in smooth muscle cells. *Sci. Signal.* 2015, 8, ra17. [CrossRef] [PubMed]

163. Lohman, A.W.; Leskov, I.L.; Butcher, J.T.; Johnstone, S.R.; Stokes, T.A.; Begandt, D.; DeLalio, L.J.; Best, A.K.; Penuela, S.; Leitinger, N.; et al. Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation. *Nat. Commun.* 2015, 6, 7965. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).